Major shareholders, board members agree to participate in placement
By Angela McDaniels
Tacoma, Wash., Oct. 5 - Amsterdam Molecular Therapeutics Holding NV aims to raise €15 million in a private placement of shares, according to a company news release.
Kempen & Co. and Petercam Nederland are the joint global coordinators and bookrunners.
The issue price and number of shares to be issued in the placement will be determined using an accelerated bookbuilding process that is expected to close on Oct. 7. The placement is expected to settle Oct. 12.
The company's key shareholders, Advent Venture Partners, Gilde Healthcare Partners, Credit Agricole Private Equity and Forbion Capital Partners, have committed to subscribe for €3.75 million in the placement, and members of the board of management plan to participate.
The proceeds will be used to fund Glybera through its regulatory and commercial development and to continue the development of the hemophilia and other pipeline programs.
The Amsterdam-based company develops human gene-based therapies.
| Issuer: | Amsterdam Molecular Therapeutics Holding NV
|
| Issue: | Shares
|
| Amount: | €15 million
|
| Warrants: | No
|
| Agents: | Kempen & Co. and Petercam Nederland
|
| Announcement date: | Oct. 5
|
| Pricing date: | Oct. 7
|
| Settlement date: | Oct. 12
|
| Stock symbol: | NYSE Euronext: AMT
|
| Stock price: | €1.90 at close Oct. 5
|
| Market capitalization: | €27.88 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
